WHO vaccine-preventable diseases: monitoring system. 2018 global summary

Last updated 1-Jun.-2018 (data as of 25-May-2018)
Next overall update Mid-July 2018
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 6'2001 Infant (under 12 months) mortality rate: 122
GDP / capita (US$): 12'4021 Child (under 5 years) mortality rate: 152

Population data in thousands3

  2017  2016  2015  2014  2013  2000  1990  1980 
Total population 32'165  31'774  31'377  30'973  30'566  25'915  21'827  17'359 
Births 609  612  615  617  618  624  660  627 
Surviving infants 599  602  605  606  607  604  620  570 
Pop. less than 5 years 3'027  3'033  3'020  3'011  2'993  3'009  3'009  2'753 
Pop. less than 15 years 8'809  8'787  8'753  8'727  8'694  8'903  8'406  7'342 
Female 15-49 years 8'459  8'385  8'310  8'230  8'148  6'758  5'421  4'054 

Number of reported cases

(Click for retrospective incidence data for Peru)
Diphtheria
ChartChart
  44  185 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  737  19'246 
Mumps
ChartChart
 
Pertussis
ChartChart
  611  143  119  236  1'373  68  1'134  12'134 
Polio*
ChartChart
  182 
Rubella
ChartChart
 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
  10  93  294 
Tetanus (total)**
ChartChart
  24  25  22  21  35  57  124  525 
Yellow fever
ChartChart
  62  24  17  21  17  30 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Peru)
Vaccine year result method % card seen                                                
BCG 2012  93  DHS   79  84  90  91  94  95  93  83  57 
DTP1 2012  93  DHS   79  90  94  97  98  97  91 
DTP3 2012  80  DHS   79  83  89  90  88  88  98  72  16 
DTP4          72  70  72  67 
IPV1          90  94  98  95 
HepB_BD          75  79  79  78  82  41 
HepB3 2012  80  DHS   79  83  89  90  88  88  44 
Hib3 2012  80  DHS   79  83  89  90  88  88  38 
JapEnc         
MCV1          83  88  92  89  85  64  23 
MCV2          66  66  63  44  54  97 
MenA         
PCV1          88  95  98  99  97 
PCV2          87  93  95  95  93 
PCV3          80  86  90  86  85 
Pol3 2012  84  DHS   79  83  88  88  78  71  93  73  16 
Rota1          88  92  95  96  95 
RotaC          85  87  87  86  86 
RCV1          83  92  45  85 
TT2plus 2013  57  DHS   87  46  27  35  36  41 
PAB         
VAD1          94  99* 
YFV          63  64  67  65  64 
* indicates the country reported above 100% coverage.

  Next update: Mid-July 2018

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Peru)
BCG
ChartChart
  91  91  94  95  93  83  57 
DTP1
ChartChart
  97  97  98  97  99  89  39 
DTP3
ChartChart
  90  90  88  88  98  72  16 
HepB3
ChartChart
  90  90  88  88 
HepB_BD
ChartChart
  79  79  78  82 
Hib3
ChartChart
  90  90  88  88  43 
IPV1
  98  98 
MCV1
ChartChart
  92  92  89  85  97  64  23 
MCV2
ChartChart
  63  63  44  54 
PCV3
ChartChart
  90  90  86  85 
Pol3
ChartChart
  88  88  78  71  93  73  16 
RCV1
ChartChart
  92  92  89  85 
RotaC
ChartChart
  87  87  86  86 
YFV
ChartChart
  67  67  65  64 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country 1'874  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90% 77
From 80 to 89% 8
From 50 to 79% 11
Less than 50% 5
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2017 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DT 2, 4, 6 months; Yes
DTwP 18 months; 4 years; Yes
DTwPHibHepB 2, 4, 6 months; Yes
HepB_Adult >5 years; Yes
HepB_Pediatric birth; Yes
HIB 2, 4, 6 months; Yes
HPV 9 years; +6 months; Yes females; grade 5, 9-13 years who not study
Influenza_Adult >18 years; Yes and elderly, adults with chronic illness, pregnant women, health care workers, other risk groups
Influenza_Pediatric 2 years; Yes and children with chronic illness
IPV 2, 4 months; Yes
MMR 12, 18 months; Yes
MR >5 years; Yes susceptibles, border areas, airports, travellers to risk areas
OPV 6, 18 months; 4 years Yes
Pneumo_conj 2. 4, 12 months; Yes
Rotavirus 2, 4 months; Yes
Td 12 years; +2, +6, +6, +6 months; Yes CBAW, pregnant women, risk groups
YF 15 months; Yes and 5-59 years in endemic and expelling areas

Immunizaton indicators

Indicator Expected answer 2017  2016  2015  2014  2013  2012  2011 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  No  No  Yes 
What years does the MYP cover? number 2015-2019  2013-2018  2016-2019  2015-2019      2011-2015 
Nº of districts with microplans that include activities to raise immunization coverage number   1'838  1'838  1'838      1'834 

System performance

Total Nº districts in country number 1'874  1'854  1'838  1'838  1'838  1'838  1'834 
Nº districts with DTP3 coverage >=80% number 1'578  1'579  804  813  774  886  862 
% of districts with DTP3 coverage >=80% From 0 to 100% 84  85  44  44  42  48  47 
Nº districts with measles (MCV1) coverage >=95% number 948  1'071  594  544  501  596  658 
% of districts with MCV1 coverage >=95% From 0 to 100% 51  58  32  30  27  32  36 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes  Yes  Yes  Yes 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100% 100    100  100  100  100  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

 1  "The 2017 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2016, data for 2018
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.